Physician profile
Iveta Boyanchek
NPI 1487621215
$2,575.61
in general payments reported to CMS, 2019-2025
23 companies · $41.21 in 2025
The $41.21 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $353 · 2021: $571 · 2022: $365 · 2023: $354 · 2024: $181 · 2025: $41.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.10 | 2021-2024 | Vraylar |
| Allergan, INC. | $400.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $358.64 | 2019-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $286.48 | 2019-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $140.48 | 2021-2025 | Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $108.21 | 2019 | |
| Supernus Pharmaceuticals, INC. | $89.39 | 2021-2022 | |
| Lundbeck LLC | $81.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.68 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $76.76 | 2021-2022 | |
| Corium, LLC | $61.78 | 2022-2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $55.54 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.21 | 2022 | |
| Ironshore Pharmaceuticals INC. | $45.40 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $39.69 | 2024 | Auvelity |
| Alkermes, INC. | $32.92 | 2021-2023 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $27.55 | 2019-2022 | |
| Adlon Therapeutics L.P. | $17.51 | 2019 | |
| Alfasigma USA, INC. | $17.10 | 2020 | |
| Tris Pharma INC | $16.72 | 2023 | Dyanavel Xr |
| Shire North American Group INC | $12.99 | 2019 | |
| Orexo US, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iveta Boyanchek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.